Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease

다국어 초록 (Multilingual Abstract)

Background/Aims: Advanced hepatic fibrosis is associated with cardiovascular disease (CVD) in patients with nonalcoholic fatty liver disease (NAFLD). We investigated the association between noninvasive serum fibrosis markers and the coronary artery calcium score (CACS) in subjects with NAFLD.
Methods: We analyzed 665 NAFLD subjects without chronic liver disease or heart disease between 2011 and 2015.
The noninvasive fibrosis markers that were used to evaluate the severity of hepatic fibrosis included the NAFLD fibrosis score (NFS), fibrosis-4 (FIB-4) score, Forn’s index, and the aspartate aminotransferase to platelet ratio index (APRI). Results: The areas under the receiver operating characteristics curves for the NFS, FIB-4 score, Forn’s index and APRI for predicting CACS >100 were 0.689, 0.683, 0.659, and 0.595, respectively. According to the multivariate analysis, older age, increased body mass index (BMI), and decreased estimated glomerular filtration rate (eGFR) were significant factors associated with CACS >100. The NFS, FIB-4 score and APRI were significantly associated with CACS >100 after adjusting for age and gender (p=0.006, p=0.012, and p=0.012, respectively) and after adjusting for age, gender, BMI and eGFR (p=0.013, p=0.022, and p=0.027, respectively). Scores integrating noninvasive fibrosis markers and other risk factors improved the predictive accuracy. Conclusions: The NFS and FIB-4 score were associated with coronary atherosclerosis in subjects with NAFLD. Furthermore, scores integrating these noninvasive scores and risk factors for CVD showed good discriminatory power in predicting CACS >100. Therefore, noninvasive serum fibrosis markers may be useful tools for identifying NAFLD subjects at a high risk for CVD.

참고문헌 (Reference)

1 Zhu Q, "Therapeutic effect of renin angiotensin system inhibitors on liver fibrosis" 17 : 1470320316628717-, 2016

2 Saadeh S, "The utility of radiological imaging in nonalcoholic fatty liver disease" 123 : 745-750, 2002

3 Adams LA, "The natural history of nonalcoholic fatty liver disease : a population-based cohort study" 129 : 113-121, 2005

4 Ampuero J, "The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity" 48 : 1260-1270, 2018

5 Chalasani N, "The diagnosis and management of non-alcoholic fatty liver disease : practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology" 142 : 1592-1609, 2012

6 Angulo P, "The NAFLD fibrosis score : a noninvasive system that identifies liver fibrosis in patients with NAFLD" 45 : 846-854, 2007

7 Bedogni G, "The Fatty Liver Index : a simple and accurate predictor of hepatic steatosis in the general population" 6 : 33-, 2006

8 Hwang IC, "Systemic Inflammation Is Associated With Coronary Artery Calcification and All-Cause Mortality in Chronic Kidney Disease" 80 : 1644-1652, 2016

9 Kwok R, "Systematic review with metaanalysis:non-invasive assessment of non-alcoholic fatty liver disease. The role of transient elastography and plasma cytokeratin-18fragments" 39 : 254-269, 2014

10 Tonelli M, "Risk of coronary events in people with chronic kidney disease compared with those with diabetes : a population-level cohort study" 380 : 807-814, 2012

11 Hajar R, "Risk factors for coronary artery disease : historical perspectives" 18 : 109-114, 2017

12 Gaia S, "Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis" 54 : 64-71, 2011

13 Targher G, "Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease" 29 : 1325-1330, 2006

14 Agatston AS, "Quantification of coronary artery calcium using ultrafast computed tomography" 15 : 827-832, 1990

15 Wilson PW, "Prediction of coronary heart disease using risk factor categories" 97 : 1837-1847, 1998

16 Castéra L, "Pitfalls of liver stiffness measurement : a 5-year prospective study of 13, 369 examinations" 51 : 828-835, 2010

17 Sinn DH, "Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis" 151 : 481-488, 2016

18 Hannah WN Jr, "Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis" 64 : 2234-2243, 2016

19 Castera L, "Noninvasive evaluation of NAFLD" 10 : 666-675, 2013

20 Wong RJ, "Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States" 148 : 547-555, 2015

21 Jaruvongvanich V, "Nonalcoholic fatty liver disease is associated with coronary artery calcification : a systematic review and meta-analysis" 48 : 1410-1417, 2016

22 Kim D, "Nonalcoholic fatty liver disease is associated with coronary artery calcification" 56 : 605-613, 2012

23 Oh H, "Non-alcoholic fatty liver diseases : update on the challenge of diagnosis and treatment" 22 : 327-335, 2016

24 Kim NH, "Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population" 100 : 938-943, 2014

25 Sinn DH, "Non-alcoholic fatty liver disease and progression of coronary artery calcium score : a retrospective cohort study" 66 : 323-329, 2017

26 Byrne CD, "NAFLD: a multisystem disease" 62 (62): S47-S64, 2015

27 Imajo K, "Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography" 150 : 626-637, 2016

28 Huwart L, "Magnetic resonance elastography for the noninvasive staging of liver fibrosis" 135 : 32-40, 2008

29 Angulo P, "Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease" 149 : 389-397, 2015

30 Sarnak MJ, "Kidney disease as a risk factor for development of cardiovascular disease : a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention" 42 : 1050-1065, 2003

31 Ong JP, "Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease" 49 : 608-612, 2008

32 Kestenbaum BR, "Incidence and progression of coronary calcification in chronic kidney disease : the Multi-Ethnic Study of Atherosclerosis" 76 : 991-998, 2009

33 Forn’ss X, "Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model" 36 (36): 986-992, 2002

34 Lee JH, "Hepatic steatosis index : a simple screening tool reflecting nonalcoholic fatty liver disease" 42 : 503-508, 2010

35 You SC, "Hepatic fibrosis assessed using transient elastography independently associated with coronary artery calcification" 30 : 1536-1542, 2015

36 Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-metaanalytic assessment of prevalence, incidence, and outcomes" 64 : 73-84, 2016

37 Ekstedt M, "Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up" 61 : 1547-1554, 2015

38 Myers RP, "Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients" 55 : 199-208, 2012

39 Wong GL, "Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population" 26 : 300-305, 2011

40 Vallet-Pichard A, "FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest" 46 : 32-36, 2007

41 European Association for Study of Liver, "EASL-ALEH Clinical Practice Guidelines : non-invasive tests for evaluation of liver disease severity and prognosis" 63 : 237-264, 2015

42 Patel K, "Diagnosis of liver fibrosis : present and future" 35 : 166-183, 2015

43 Wong VW, "Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease" 51 : 454-462, 2010

44 Sinn DH, "Development of chronic kidney disease in patients with non-alcoholic fatty liver disease : a cohort study" 67 : 1274-1280, 2017

45 Detrano R, "Coronary calcium as a predictor of coronary events in four racial or ethnic groups" 358 : 1336-1345, 2008

46 Greenland P, "Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals" 291 : 210-215, 2004

47 Polonsky TS, "Coronary artery calcium score and risk classification for coronary heart disease prediction" 303 : 1610-1616, 2010

48 Ichikawa S, "Comparison of the diagnostic accuracies of magnetic resonance elastography and transient elastography for hepatic fibrosis" 33 : 26-30, 2015

49 Bedossa P, "Biopsy and noninvasive methods to assess progression of nonalcoholic fatty liver disease" 150 : 1811-1822, 2016

50 Kamal S, "Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease : a systematic review and meta-analysis" 112 : 1495-1505, 2017

51 Kim D, "Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States" 57 : 1357-1365, 2013

52 Wai CT, "A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C" 38 : 518-526, 2003

53 Levey AS, "A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group" 130 : 461-470, 1999